Clinical Trial

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-20.
Status change: Not Yet Recruiting → Recruiting 2026-03-10
Trial Details
NCT Number NCT07372625
Lead Sponsor PMV Pharmaceuticals, Inc
Collaborators: SCRI Development Innovations, LLC
Conditions TP53 Y220C Mutation, Advanced Solid Tumors
Enrollment 14 participants
Start Date 2026-02-04
Primary Completion 2027-03 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12